Illumina Will Retire Its NovaSeq X Transition Slide After The Fourth Quarter, CFO Says

About 84% of high-throughput volume now runs on the newer sequencer, and clinical customers at 78% are the holdouts.

Share
Illumina Will Retire Its NovaSeq X Transition Slide After The Fourth Quarter, CFO Says

Illumina will stop showing its NovaSeq X transition slide in earnings presentations after the fourth quarter of 2026, CFO Ankur Dhingra said on the company's third-quarter earnings call Thursday, because roughly 84% of high-throughput volume has already moved to the new platform.

Where the conversion stands

Dhingra said about 84% of high-throughput volume and 60% of revenue now runs on the NovaSeq X, the company's newer sequencer. He said the charts are "becoming less relevant" for showing the price and volume dynamics behind revenue growth.

Research and applied customers have run at 90% or more of volume on the X for each of the last five quarters, which Dhingra said means minimal transition pricing headwinds from them going forward.

Clinical lags at 78% of volume. Dhingra said some clinical customers keep current assays on the older 6K while adding X capacity only for new tests, and the pace of conversion has slowed in recent quarters. He expects clinical to reach 80% to 85% in coming quarters, so the year-over-year pricing headwinds from the transition should be lower in 2027 than in 2026.

Pricing questions from analysts

An analyst from Piper Sandler pressed on what discounts big clinical customers will extract as volumes grow. CEO Jacob Thaysen called that "very specific" and did not give a number. He said Illumina is willing to discuss price with customers who sign up for large volumes or bring new, sequencing-intensive assays.

Thaysen said he does not see pull-forward in X demand. Illumina placed over 80 instruments in the quarter, about 360 over the last four quarters, which he said is more than in the first year of launch. Dhingra said gigabase output growth on connected high- and mid-throughput instruments stayed above 30%.

Quarter and raised outlook

Dhingra said revenue was $1.17 billion on an adjusted basis excluding tariff refunds, up 4.7% year over year on a rest-of-world organic basis. Diluted EPS was $1.44, up 7%, and operating margin was 25%. Sequencing consumables revenue was $792 million.

Illumina raised full-year revenue guidance by $30 million at the midpoint, to $4.64 billion to $4.66 billion, and EPS guidance to $5.40 to $5.45. For the fourth quarter it expects revenue of $1.22 billion to $1.24 billion and EPS of $1.51 to $1.56. Illumina's market value was $43.6 billion as of Thursday evening.

The fourth-quarter call will carry the last transition slide and Illumina's first 2027 guidance, which Thaysen said the company will give then.

Sources

More on Illumina

All Illumina (ILMN) coverage →